CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

Press releases


CHEPLAPHARM strengthens its oncology portfolio

more chevron_right
Press releases


CHEPLAPHARM acquires rights to CMV medicine

more chevron_right
Press releases


CHEPLAPHARM continues profitable growth track in 2021 as well

more chevron_right
Press releases


Significant and sustainable site expansion

more chevron_right
Press releases


CHEPLAPHARM acquires additional oncology drugs

more chevron_right
Press releases


Jens Rothstein hands over his CFO role to Kia Parssanedjad

more chevron_right
Investor Relations


CHEPLAPHARM announces successful pricing of Term Loan B

more chevron_right
Archive Press releases


CHEPLAPHARM continues strong Growth

more chevron_right
Press releases


CHEPLAPHARM signed deal

more chevron_right
Press releases


CHEPLAPHARM invests in portfolio of anti-infectives

more chevron_right

Investor Relations topics

Back to top expand_less